MS INTERNATIONAL PLC — Director's Dealing 2022

Apr 7, 2022

National Storage Mechanism | Additional information

RNS Number : 5291H

SourceBio International PLC

07 April 2022

SourceBio International plc

("SourceBio", the "Company" or the "Group")

Director's Share Purchase

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products, announces that on 6 April 2022, Jay LeCoque, Executive Chairman, purchased 100,000 Ordinary Shares in the Company at a price of 129.5 pence per Ordinary Share, representing 0.14% of the Company's issued share capital.

Jay LeCoque's total shareholding now comprises 2,444,612 Ordinary Shares, representing 3.30% of the Company's issued share capital.

Contacts: 

SourceBio International plc		www.sourcebiointernational.com
Jay LeCoque, Executive Chairman		Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Advisor and Broker)		Tel: 020 3100 2000
Richard Lindley / William Hall
Walbrook PR Limited	Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen		Mob: 07980 541 893 / 07502 558 258

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

·    Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare providers across the UK and Ireland, including Digital Pathology

·    Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America

·    Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA

·    Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits and venue testing.

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange. 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jay LeCoque

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

SourceBio International Plc

b)

LEI

213800KY4C9WU7WBW518

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of  £0.0015 each

Identification code

GB00BKSB1674

b)

Nature of the transaction

Purchase of 100,000 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
129.5 pence	100,000

d)

Aggregated information

Volume

Price

N/A - single transaction

e)

Date of the transaction

6 April 2022

f)

Place of the transaction

London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSSEFIMEESEFL